Validation of an analytical method for a potent antitumor agent, TZT-1027, in plasma using liquid chromatography–mass spectrometry

Ochiai, Hiroyuki; Mori, Hiromi; Murata, Hideyuki; Seki, Toshimi; Araki, Keiko; Kawabe, Yoshihiro; Miyazaki, Kei; Tsukamoto, Kunio; Iwamura, Satoshi

doi:10.1016/s0378-4347(01)00360-7

Cited by 7 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following IV administration of the drug the N ‐demethylated metabolite could be identified. Later, Ochiai et al (2001) published a sensitive LC‐APCI‐MS assay for the determination of the dolastatin‐10 derivative TZT‐1027 in human, dog, rat, mouse, and monkey plasma.…”

Section: Antimitotic Agentsmentioning

confidence: 99%

Liquid chromatography‐mass spectrometry for the quantitative bioanalysis of anticancer drugs

Stokvis

Rosing

Beijnen

2004

Mass Spectrometry Reviews

View full text Add to dashboard Cite

The monitoring of anticancer drugs in biological fluids and tissues is important during both pre‐clinical and clinical development and often in routine clinical use. Traditionally, liquid chromatography (LC) in combination with ultraviolet (UV), fluorescence, or electrochemical detection is employed for this purpose. The successful hyphenation of LC and mass spectrometry (MS), however, has dramatically changed this. MS detection provides better sensitivity and selectivity than UV detection and, in addition, is applicable to a significantly larger group of compounds than fluorescence or electrochemical detection. Therefore, LC‐MS has now become the method of first choice for the quantitative bioanalysis of many anticancer agents. There are still, however, a lot of new developments to be expected in this area, such as the introduction of more sensitive and robust mass spectrometers, high‐throughput analyses, and further optimization of the coupled LC systems. Many articles have appeared in this field in recent years and are reviewed here. We conclude that LC‐MS is an extremely powerful tool for the quantitative analysis of anticancer drugs in biological samples. © 2004 Wiley Periodicals, Inc., Mass Spec Rev 24:887–917, 2005

show abstract

Section: Antimitotic Agentsmentioning

confidence: 99%

Liquid chromatography‐mass spectrometry for the quantitative bioanalysis of anticancer drugs

Stokvis

Rosing

Beijnen

2004

Mass Spectrometry Reviews

View full text Add to dashboard Cite

show abstract

Sample Preparation for LC‐MS Bioanalysis of Peptides

Yuan¹

2019

Sample Preparation in LC‐MS Bioanalysis

View full text Add to dashboard Cite

Interactions of antimitotic peptides and depsipeptides with tubulin

Hamel

2002

Biopolymers

View full text Add to dashboard Cite

Tubulin is the target for an ever increasing number of structurally unusual peptides and depsipeptides isolated from a wide range of organisms. Since tubulin is the subunit protein of microtubules, the compounds are usually potently toxic to mammalian cells. Without exception, these (depsi)peptides disrupt cellular microtubules and prevent spindle formation. This causes cells to accumulate at the G2/M phase of the cell cycle through inhibition of mitosis. In biochemical assays, the compounds inhibit microtubule assembly from tubulin and suppress microtubule dynamics at low concentrations. Most of the (depsi)peptides inhibit the binding of Catharanthus alkaloids to tubulin in a noncompetitive manner, GTP hydrolysis by tubulin, and nucleotide turnover at the exchangeable GTP site on beta-tubulin. In general, the (depsi)peptides induce the formation of tubulin oligomers of aberrant morphology. In all cases tubulin rings appear to be formed, but these rings differ in diameter, depending on the (depsi)peptide present during their formation.

show abstract

Validation of an analytical method for a potent antitumor agent, TZT-1027, in plasma using liquid chromatography–mass spectrometry

Cited by 7 publications

References 5 publications

Liquid chromatography‐mass spectrometry for the quantitative bioanalysis of anticancer drugs

Liquid chromatography‐mass spectrometry for the quantitative bioanalysis of anticancer drugs

Sample Preparation for LC‐MS Bioanalysis of Peptides

Interactions of antimitotic peptides and depsipeptides with tubulin

Contact Info

Product

Resources

About